Synthego, the genome engineering company, today announced it has adopted Good Manufacturing Practice (GMP) standards to provide academic and industry partners with high-quality reagents for use in clinical research and development (R&D).
CollPlant, a regenerative medicine company, today announced it is now part of a new public-private ManufacturingUSA initiative, the Advanced Regenerative Manufacturing Institute (ARMI).
GE Healthcare Life Sciences and Advanced Solutions Life Sciences (ASLS) will enter into a strategic R&D and distribution partnership that sets out to personalize tissue regeneration.
Nephron Pharmaceuticals Corporation today announced a new partnership with National Medical Products Inc. – developer of the J-Tip Needle Free Injector – that provides patients with an easy-to-use and virtually pain-free delivery of anesthetic medications prior to medical procedures.
SpendEdge, a global procurement market intelligence firm, has announced the release of its Global Pharmaceutical Drug Development Services Market - Procurement Intelligence Report.
Israeli medical cannabis company InterCure Ltd. announced that its wholly-owned subsidiary Canndoc initiated a phase 3 clinical trial with the Shamir Medical Center (Assaf HaRofeh) for the treatment of children with autism spectrum disorder.
Causaly, the AI company teaching computers to read, understand and interpret biomedical knowledge, is pleased to announce its series A fundraising round, which saw new and existing investors commit $4.8m into the company.
MTF Biologics, a global nonprofit organization dedicated to saving and healing lives through organ and tissue donation, is introducing Leneva™ – Allograft Adipose Matrix and SomaGen™ Meshed – Allograft Dermal Matrix to its line of premier, innovative and effective wound care solutions.
Fresenius Kabi announced today the immediate availability in the United States of Fosaprepitant for Injection 150 mg per vial, the newest addition to the company’s generic oncology portfolio.
Vertex Pharmaceuticals Incorporated today announced the U.S. Food and Drug Administration (FDA) has approved TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and...